Scholarlink

Purpose <p>To evaluate the prevalence of hypogonadotropic hypogonadism (HH) in male prolactinoma patients with dopamine agonist (DA) therapy and explore the predictive factors of hypogonadism recovery.</p> Design <p>Retrospective study from a single center.</p> Methods <p>A cohort of male prolactinoma patients who were under medical therapy for at least one year with regular follow-up from the special outpatient clinic in Huashan Hospital was reviewed. Demographic details, clinical features, hormonal profile, medication, imaging characteristics were recorded at diagnosis and during the timeline follow-up.</p> Findings <p>A total of 73 male prolactinoma patients with median age of 35 (31–51) years old, and BMI of 24.9&#xa0;± 2.7&#xa0;kg/m<sup>2</sup> were included. The prevalence of HH at diagnosis was 87.7%. After 2.5 (1.5–3.4) years of DA therapy, 71.4% of HH patients recovered after prolactin normalization. Compared to those with persistent HH, patients with HH recovery had lower baseline BMI (24.2 ± 2.4 vs. 26.4 ± 2.7&#xa0;kg/m<sup>2</sup>, <i>p</i> = 0.002), and higher baseline testosterone (4.28 [3.32–6.03] vs. 2.34 [1.36–4.35] nmol/L, <i>p</i> = 0.007). The multivariate logistic regression analysis demonstrated that patients with higher testosterone level (OR 1.679 [1.134–2.487]) or lower BMI (OR 0.761 [0.592–0.977]) at diagnosis had significantly greater possibility of HH recovery, after adjusting for prolactin, adenoma maximal diameter and vision changes.</p> Conclusions <p>HH is common in male prolactinoma patients and 71.4% of them recovered from HH after prolactin normalization treated by DA. Baseline testosterone and BMI were identified as independent predictors of HH recovery in men with prolactinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists

  • 期刊论文

  • 发表日期：

    2025年9月20日

查看全文
  • Yuanpin Zhang,
  • Yujia Li,
  • Qiaoli Cui,
  • Hangping Zheng,
  • Wanwan Sun,
  • Lili Chen,
  • Xiaoming Zhu,
  • Yiming Li,
  • Hongying Ye,
  • Shuo Zhang,
  • Xiaoxia Liu,
  • Lijin Ji

摘要

Purpose

To evaluate the prevalence of hypogonadotropic hypogonadism (HH) in male prolactinoma patients with dopamine agonist (DA) therapy and explore the predictive factors of hypogonadism recovery.

Design

Retrospective study from a single center.

Methods

A cohort of male prolactinoma patients who were under medical therapy for at least one year with regular follow-up from the special outpatient clinic in Huashan Hospital was reviewed. Demographic details, clinical features, hormonal profile, medication, imaging characteristics were recorded at diagnosis and during the timeline follow-up.

Findings

A total of 73 male prolactinoma patients with median age of 35 (31–51) years old, and BMI of 24.9 ± 2.7 kg/m2 were included. The prevalence of HH at diagnosis was 87.7%. After 2.5 (1.5–3.4) years of DA therapy, 71.4% of HH patients recovered after prolactin normalization. Compared to those with persistent HH, patients with HH recovery had lower baseline BMI (24.2 ± 2.4 vs. 26.4 ± 2.7 kg/m2, p = 0.002), and higher baseline testosterone (4.28 [3.32–6.03] vs. 2.34 [1.36–4.35] nmol/L, p = 0.007). The multivariate logistic regression analysis demonstrated that patients with higher testosterone level (OR 1.679 [1.134–2.487]) or lower BMI (OR 0.761 [0.592–0.977]) at diagnosis had significantly greater possibility of HH recovery, after adjusting for prolactin, adenoma maximal diameter and vision changes.

Conclusions

HH is common in male prolactinoma patients and 71.4% of them recovered from HH after prolactin normalization treated by DA. Baseline testosterone and BMI were identified as independent predictors of HH recovery in men with prolactinoma.